Nuvalent, Inc. Class A Common Stock
NUVL
$123.96
+0.02%
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted small-molecule therapies for patients with cancer, operating entirely in the United States. The company distinguishes itself by developing next-generation kinase inhibitors designed to overcome resistance and limitations of existing therapies, with a pipeline targeting ROS1-positive non-small cell lung cancer (NSCLC), ALK-positive NSCLC, and HER2ex20-driven tumors. The current investor narrative is dominated by GSK's $10.6 billion acquisition announcement in June 2026, which has driven the stock to near its 52-week high and shifted attention to the deal's completion and long-term strategic fit within GSK's oncology portfolio.…
NUVL
Nuvalent, Inc. Class A Common Stock
$123.96
Related headlines
Investment Opinion: Should I buy NUVL Today?
Rating: Hold. The stock is a hold given the high probability of the GSK acquisition closing, which offers a modest 8.7% upside to the implied deal price of ~$134.70. The analyst consensus has shifted to neutral following the acquisition announcement, with multiple downgrades from buy to hold. The average target price is not explicitly provided, but the deal price serves as a de facto target.
Supporting Evidence: The acquisition provides a floor at ~$123.96, with upside to $134.70. The company has zero debt and a current ratio of 15.3, indicating strong liquidity. The stock's 1-year return of +46.5% significantly outperforms the S&P 500's +21.3%. However, the company has no revenue and negative earnings, with a trailing P/E of -17.2 and forward P/E of -30.0. The P/B ratio of 5.86 is above the industry average, but justified by the acquisition premium.
Risks & Conditions: The primary risk is deal failure, which could send the stock to $71.13 (52-week low). This Hold would upgrade to Buy if the acquisition price is increased or if the stock dips significantly below the deal price, offering a higher margin of safety. It would downgrade to Sell if the deal is called off or if new information suggests a lower probability of completion. Overall, the stock is fairly valued relative to the acquisition price, but overvalued on a standalone basis without the deal.
Sign up to view all
NUVL 12-Month Price Forecast
The outlook for Nuvalent over the next 12 months is bullish, driven by the high-probability GSK acquisition. The base case of a successful deal closure is most likely (65% probability), with the stock converging to the implied price of ~$134.70. The bull case (20%) includes potential for a higher bid, while the bear case (15%) of deal failure poses significant downside. The stock's low volatility and tight trading range near the 52-week high indicate market confidence in the deal. Key factors supporting the bullish stance include the acquisition premium, strong balance sheet, and validated pipeline. The stance would be downgraded to neutral if deal completion probability falls below 50%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Nuvalent, Inc. Class A Common Stock's 12-month outlook, with a consensus price target around $125.13 and implied upside of +0.9% versus the current price.
Average Target
$125.13
0 analysts
Implied Upside
+0.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$124 - $140
Analyst target range
Nuvalent is covered by 15 analysts, but the consensus recommendation and average target price are not directly provided. However, recent institutional ratings show a wave of downgrades following the GSK acquisition announcement, with firms like Bernstein, UBS, TD Cowen, Wedbush, Truist, Guggenheim, Barclays, HC Wainwright, and LifeSci Capital all downgrading the stock to neutral/hold from buy/outperform. This suggests the consensus has shifted to neutral, as the acquisition price likely caps upside. The average target price is not available, but the acquisition price of $10.6 billion implies a per-share value of approximately $134.70 (based on 78.7 million shares outstanding), which is about 8.7% above the current price of $123.96. This implies a modest upside to the deal price. The target range is not provided, but the high target likely assumes a successful acquisition at the announced price or higher, while the low target may reflect deal risk or a lower valuation if the acquisition fails. The wide spread of analyst actions (all downgrades) indicates high uncertainty about the stock's standalone value post-acquisition, but the tight clustering of neutral ratings suggests conviction that the stock will trade near the acquisition price until the deal closes.
Drowning in data?
Find the real signal!
Bulls vs Bears: NUVL Investment Factors
Nuvalent presents a unique investment case dominated by the GSK acquisition, which provides a clear floor and modest upside to the deal price. The bull case rests on the validated pipeline, strong balance sheet, and acquisition premium, while the bear case highlights zero revenue, widening losses, and limited upside potential. Currently, the bull case has stronger evidence due to the high probability of deal completion, but the stock's near-term upside is capped. The single most important tension is whether the acquisition closes as expected; if it does, investors realize a ~8.7% gain, but if it fails, the stock could fall sharply toward its 52-week low of $71.13, a potential 42.6% decline.
Bullish
- GSK Acquisition at $10.6B: GSK announced a $10.6 billion acquisition on June 9, 2026, implying a per-share value of ~$134.70, an 8.7% upside from the current price of $123.96. This provides a clear floor and near-term upside for shareholders.
- Strong Pipeline with Next-Gen Kinase Inhibitors: Nuvalent's pipeline includes NVL-520 (ROS1+ NSCLC), NVL-655 (ALK+ NSCLC), and NVL-330 (HER2ex20), targeting validated kinase targets with potential to overcome resistance. The acquisition by GSK validates the pipeline's value.
- Zero Debt and High Liquidity: The company has a debt-to-equity ratio of 0 and a current ratio of 15.3, with $159.7 million in cash as of Q1 2026. This strong balance sheet reduces financial risk and supports ongoing R&D.
- Significant Relative Strength: The stock has outperformed the S&P 500 by 25.2% over the past year and surged 57.6% in the last month following the acquisition news, demonstrating strong momentum and investor confidence.
Bearish
- No Revenue and Deep Losses: Nuvalent has zero revenue and reported a net loss of $109.3 million in Q1 2026, with losses widening year-over-year. The company is entirely pre-commercial, with no path to profitability without successful drug approvals.
- Acquisition Caps Upside Potential: With the GSK acquisition at $10.6 billion, the stock is trading near the implied deal price of ~$134.70, limiting further upside to ~8.7%. Multiple analysts have downgraded the stock to neutral, reflecting limited near-term gains.
- High Cash Burn Rate: Free cash flow was -$92.4 million in Q1 2026 and -$312.8 million over the trailing twelve months. Cash reserves of $159.7 million provide less than two quarters of runway, necessitating future financing or acquisition completion.
- Elevated Valuation on Book Value: The price-to-book ratio of 5.86 is above the biotech industry average of 3-4x, implying a premium that is justified only by the acquisition. Without the deal, the stock would likely trade lower.
NUVL Technical Analysis
Nuvalent is in a sustained uptrend, with the stock price up 46.5% over the past year and currently trading at $123.96, representing 99.98% of its 52-week range of $71.13 to $123.99. This positioning near the high end of the range reflects strong momentum and investor optimism, though it also suggests the stock may be overextended in the near term. The 1-year price change of +46.5% significantly outperforms the S&P 500's +21.3% over the same period, highlighting the stock's relative strength. Short-term momentum is robust, with a 1-month price change of +57.6% and a 3-month change of +18.3%, indicating accelerating momentum. The 1-month surge of 57.6% aligns with the GSK acquisition news on June 9, 2026, which caused a sharp price jump from around $90 to $123, and the stock has since consolidated near those levels. This divergence from the longer-term trend is a clear catalyst-driven breakout rather than a mean reversion signal. The stock's beta of 1.138 indicates slightly higher volatility than the market, but the recent price action has been remarkably stable since the acquisition announcement, with daily closes tightly clustered between $123.25 and $123.96. Key support is at the 52-week low of $71.13, while resistance is at the 52-week high of $123.99. A breakout above $123.99 would signal continued upside momentum, potentially toward the acquisition price implied by GSK's $10.6 billion offer. The stock's low volatility post-announcement suggests the market is pricing in a high probability of deal completion, reducing downside risk.
Beta
1.14
1.14x market volatility
Max Drawdown
-21.0%
Largest decline past year
52-Week Range
$71-$124
Price range past year
Annual Return
+46.5%
Cumulative gain past year
| Period | NUVL Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +0.6% |
| 3m | +18.3% | +6.3% |
| 6m | +16.8% | +9.1% |
| 1y | +46.5% | +20.9% |
| ytd | +22.9% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NUVL Fundamental Analysis
Nuvalent is a pre-revenue clinical-stage biotech with zero revenue in the most recent quarter (Q1 2026) and no revenue in any historical period. The company's growth trajectory is entirely dependent on pipeline progress and regulatory milestones, with no revenue to analyze. The lack of revenue is typical for early-stage biotechs, and the investment case hinges on the success of its clinical programs, particularly NVL-520, NVL-655, and NVL-330. The company is unprofitable, reporting a net loss of -$109.3 million in Q1 2026, compared to -$118.7 million in Q4 2025 and -$84.6 million in Q1 2025. The net loss has widened over the past year, reflecting increased R&D spending (R&D expenses were $83.6 million in Q1 2026 vs. $74.4 million in Q1 2025). Gross margin is not applicable as there is no revenue. The company's operating margin is deeply negative, with operating expenses of $119.4 million in Q1 2026. The trajectory toward profitability is uncertain and depends on future product approvals and commercialization. Nuvalent has a strong balance sheet with zero debt (debt-to-equity ratio of 0) and a current ratio of 15.3, indicating ample liquidity. Cash and equivalents were $159.7 million at the end of Q1 2026, down from $261.7 million at the end of 2025, reflecting cash burn from operations. Free cash flow was -$92.4 million in Q1 2026, and trailing twelve-month free cash flow was -$312.8 million. The company has historically funded operations through equity offerings, including a $500 million common stock issuance in Q4 2025. ROE is -34.1%, reflecting negative shareholder equity returns due to accumulated losses. The strong liquidity position provides a runway for continued R&D investment, but the negative free cash flow underscores the need for future financing or successful commercialization.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-312787000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NUVL Overvalued?
Since Nuvalent has negative net income and negative EBITDA, the appropriate valuation metric is the price-to-sales (P/S) ratio, but the company has zero revenue, making P/S undefined. Therefore, we use the price-to-book (P/B) ratio as a secondary measure. The current P/B ratio is 5.86, based on the most recent quarter. The trailing P/E is -17.2 and forward P/E is -30.0, both negative due to losses, so they are not meaningful. The P/B ratio of 5.86 is elevated relative to the biotech industry average, which typically trades around 3-4x book value. This premium is justified by the company's strong pipeline and the acquisition premium from GSK's $10.6 billion offer, which values the company at a significant premium to book value. Historically, Nuvalent's P/B ratio has ranged from 2.4 (Q1 2022) to 7.7 (Q2 2024), with the current level of 5.86 near the middle of that range. The current P/B is below the peak of 7.7 seen in mid-2024, suggesting that while the stock is not at historical extremes, it is still priced at a premium to its own history. The acquisition offer provides a floor for valuation, but the lack of revenue and earnings means traditional valuation metrics are less relevant, and the stock's value is largely driven by the deal price.
PE
-17.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-672.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Nuvalent's primary financial risk is its pre-revenue status and significant cash burn. The company reported a net loss of $109.3 million in Q1 2026, with R&D expenses of $83.6 million. Free cash flow was -$92.4 million in the quarter, and cash reserves of $159.7 million provide less than two quarters of runway at the current burn rate. The company has historically relied on equity offerings, including a $500 million issuance in Q4 2025, which dilutes shareholders. Without the GSK acquisition, Nuvalent would need additional financing to continue operations, posing a risk of further dilution or financial distress.
Market & Competitive Risks: The stock's valuation is entirely dependent on the GSK acquisition, with a P/B ratio of 5.86 above the biotech industry average. If the deal fails due to regulatory or shareholder issues, the stock could revert to pre-acquisition levels around $90, a 27% decline. The company faces competition from existing therapies for ROS1 and ALK-positive NSCLC, and its pipeline candidates are still in clinical stages. The beta of 1.138 indicates slightly higher volatility than the market, but post-acquisition, the stock has shown low volatility, reflecting high deal certainty.
Worst-Case Scenario: If the GSK acquisition fails (e.g., due to antitrust concerns or shareholder rejection), Nuvalent would likely trade down to its 52-week low of $71.13, a 42.6% decline from the current price of $123.96. This scenario could be triggered by regulatory hurdles or a competing bid falling through. The company's cash burn would then become a critical issue, potentially forcing a dilutive financing or a lower acquisition offer.
FAQ
The primary risk is deal failure: if the GSK acquisition does not close, the stock could fall to $71.13 (52-week low), a 42.6% decline. Financial risk includes cash burn: free cash flow was -$92.4 million in Q1 2026, and cash reserves of $159.7 million provide less than two quarters of runway. Competitive risk: Nuvalent's pipeline faces competition from existing therapies for ROS1 and ALK-positive NSCLC. Regulatory risk: the deal may face antitrust scrutiny. The most severe risk is deal failure, which would also expose the company's need for additional financing.
The 12-month forecast is dominated by the GSK acquisition. The base case (65% probability) expects the stock to trade in a range of $123-$134.70, converging to the deal price. The bull case (20% probability) sees the stock reaching $134.70-$140 if a competing bid emerges or the deal closes smoothly. The bear case (15% probability) sees the stock falling to $71.13-$90 if the deal fails. The most likely scenario is the base case, with the stock gradually moving toward the acquisition price. Analyst consensus is neutral, reflecting limited upside.
NUVL is fairly valued relative to the GSK acquisition price of $10.6 billion, which implies a per-share value of ~$134.70, about 8.7% above the current price. On a standalone basis, the stock is overvalued with a P/B ratio of 5.86, above the biotech industry average of 3-4x. The company has no revenue, negative earnings (trailing P/E of -17.2), and negative free cash flow. The premium is justified only by the acquisition. Without the deal, the stock would likely trade at a lower multiple, suggesting it is overvalued based on fundamentals.
NUVL is a good buy for investors seeking a low-risk arbitrage opportunity with a modest 8.7% upside to the GSK acquisition price of ~$134.70. The stock has strong support from a zero-debt balance sheet and a current ratio of 15.3, but it has no revenue and negative earnings. The biggest downside risk is deal failure, which could send the stock to $71.13 (52-week low). For risk-averse investors, the current price near $123.96 offers a favorable risk/reward if the deal closes. However, for long-term growth investors, the capped upside makes it less attractive. Overall, it is a buy for merger arbitrageurs but a hold for others.
NUVL is best suited for short-to-medium-term investment, specifically as a merger arbitrage play until the GSK acquisition closes (expected in Q3 2026). The stock's beta of 1.138 indicates slightly higher volatility, but post-acquisition, it has shown low volatility. The company has no dividend and negative earnings, making it unsuitable for income investors. For long-term investors, the capped upside and lack of standalone revenue make it less attractive. A concrete holding period of 3-6 months until deal closure is recommended. After the acquisition, the stock will likely be delisted.
